SLT as First-Line Glaucoma Treatment: The LiGHT Trial Explained
Last updated: October 2026
Key points in 60 seconds
LiGHT: 718 treatment-naive patients randomised to SLT first or drops first.
At 3 years, about 74% of SLT eyes were drop-free at target; quality of life was similar.
At 6 years: less progression (19.6% vs 26.8%) and fewer trabeculectomies with SLT first.
NICE now recommends offering SLT first for OAG and ocular hypertension.
For most of our careers, newly diagnosed glaucoma meant a prostaglandin drop. The LiGHT trial changed that. Selective laser trabeculoplasty (SLT) given first kept most eyes drop-free, controlled the disease at least as well, and prevented more surgery. In the UK, NICE now recommends offering SLT first.
The LiGHT trial
Design: 718 treatment-naive patients with open-angle glaucoma or ocular hypertension were randomised to SLT first or eye drops first, then treated to an individual target IOP with escalation as needed.
Primary outcome: health-related quality of life (EQ-5D) at 3 years. Clinical outcomes, cost-effectiveness and safety were secondary.
Outcome
3 years (Lancet 2019)
6 years (Ophthalmology, published 2022)
Quality of life
No difference between arms
No significant difference
Drop-free at target, SLT arm
About 74%
69.8%
Disease progression
—
19.6% SLT vs 26.8% drops
Trabeculectomy
None in SLT arm vs 11 in drops arm
13 SLT vs 32 drops
Cataract surgery
—
57 SLT vs 95 drops
Cost
SLT about 90% likely to be more cost-effective
—
What guidelines say now
NICE (NG81, updated 2022): offer SLT as first-line treatment for newly diagnosed ocular hypertension and open-angle glaucoma.
AAO Preferred Practice Pattern and European Glaucoma Society: list laser trabeculoplasty as an acceptable initial therapy alongside medication.
Drops remain appropriate when SLT is unavailable, unaffordable, contraindicated, or not the patient's preference.
How SLT works and how it is done
Parameter
SLT
ALT (for contrast)
Laser
Q-switched, frequency-doubled Nd:YAG, 532 nm
Argon, 488/514 nm
Spot size
400 µm (covers the whole trabecular meshwork)
50 µm
Pulse duration
3 nanoseconds
0.1 seconds
Energy
Typically 0.4–1.2 mJ, titrated to just below or at "champagne bubble" formation
Titrated to blanching
Tissue effect
Selective photothermolysis of pigmented TM cells. Biological (cytokine and macrophage) response, no coagulative scarring.
Coagulative burns and scarring
Repeatable
Yes
Limited
LiGHT used 360° treatment with about 100 non-overlapping spots.
Give an alpha-agonist (apraclonidine or brimonidine) to blunt the post-laser IOP spike, and check IOP about an hour later in advanced disease.
Full effect takes 6–8 weeks; review then before judging success.
Low-energy annual repeat SLT is being tested (the COAST trial).
When to be careful
Heavily pigmented angles (pigment dispersion, pseudoexfoliation): use lower energy, as IOP spikes are more likely.
Angle closure: the trabecular meshwork must be visible. SLT is not a treatment for closed angles.
Uveitic glaucoma: generally avoid.
Very high IOP or advanced field loss: SLT alone may not reach target, so plan escalation early.
Rare complications: transient iritis, hyphema, and corneal oedema or haze (reported mainly in high myopes).
Viva pearls
SLT: 532 nm, 3 ns, 400 µm. ALT: 50 µm, 0.1 s.
LiGHT's primary outcome was quality of life, not IOP. A common viva trap.
SLT works in pseudophakic eyes and can be repeated.
Best responders tend to have higher pre-treatment IOP.
Patel D. SLT as First-Line Glaucoma Treatment: The LiGHT Trial Explained. RPC Rounds (Sadbhaav Eye Clinic). Updated October 2026. Available at: https://www.sadbhaavclinic.com/slt-first-line-light-trial.html. Accessed [date].
Written and medically reviewed by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi) · Editorial policy